On the vaccine front, American biotech firm Moderna was one of the first companies in the world to react to the Covid-19 outbreak back in January.
Alongside the US NIH (National Institute of Health), it began working on its mRNA-1273 vaccine candidate before the first coronavirus cases outside of China had been confirmed.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This potential Covid-19 vaccine has since entered clinical trials, received a funding boost of close to $500m and been fast-tracked through regulatory protocols by the US Food and Drug Administration (FDA).
With Moderna joining Pfizer, Merck, Johnson & Johnson and AstraZeneca as the “finalists” in Donald Trump’s Operation Warp Speed last week, we take a closer look at how this relatively young biotech company moved to the forefront of the race to find a coronavirus vaccine.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
